



ST PHARM

cGMP compliant ST Pharm is providing top manufacturing services to satisfy our customers' high expectations to use our products in pharmaceutical industry. As a member of Dong-A Socio Holdings, ST Pharm is proactively investing our manufacturing equipments to provide cutting edge services which are comprehensive and matching to the fast phased global market. ST Pharm will continually challenge ourselves to prosper as not only a leading pharmaceutical company but also a global chemical company.

Main Products

Category	Products	Customer	Indication/Stage
New Drug APIs	HCV drug	Originator (Global)	HCV/Marketed
	Diabetes drug	Originator (Global)	Diabetes/Marketed
	Antibiotics drug	Originator (Global)	Antibiotics/Marketed
	Gastric Cancer	Originator (Global)	Gastric Cancer / Phase 3
	Mitochondrial DNA Depletion Syndrome	Originator (Global)	MDDs/Phase 3
Pharmaceutical Intermediates	Chiral epoxide	Originator (Global)	HIV/Marketed
	Chloro-(L)-sugar	Originator (Global)	HBV/Marketed
	Nucleoside monomers	US/EP/JP	Various RNA therapeutics/Clinical
APIs	Atorvastatin	Domestic/JP	Hyperlipidemia/Marketed
	Clopidogrel	Domestic	Anticoagulant/Marketed
	d-Cycloserine	Domestic/JP/WHO/ROW	Tuberculosis/Marketed
	Terizidone	S.Africa/Germany/CIS	Tuberculosis/Marketed
	Gadobutrol	Domestic/EU/CIS	MRI contract/Marketed

R&D Pipeline

Category	Project (Indications)	Stage (on going)
New Drug	STP1002 (cancer)	Phase I
	STP0404 (HIV ALLINI)	Phase I
	STP3725 (Anticoagulants)	Preclinical
	NASH	Discovery
	IBD	Discovery
	Influenza	Discovery

CEO
Kyungjin Kim

Location
231, Hyeomnyeok-ro, Siheung-si, Gyeonggi-do, 15086 Korea

Specialty
Oligo APIs and New Drug Development, CMO(New Drug APIs & Intermediates), Generic APIs

Tel / Fax / E-mail
T. 82-2-527-6351
F. 82-2-561-6006
E. ywshin@stpharm.co.kr